IRIS
CICCARELLI, LEONARDINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.064
EU - Europa 1.523
AS - Asia 1.240
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 4.834
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.041
CN - Cina 1.199
IE - Irlanda 516
UA - Ucraina 367
FI - Finlandia 226
DE - Germania 211
SE - Svezia 98
IT - Italia 59
GB - Regno Unito 29
CA - Canada 23
SG - Singapore 13
IN - India 12
NL - Olanda 8
IR - Iran 6
JO - Giordania 6
FR - Francia 5
EU - Europa 4
NZ - Nuova Zelanda 3
AT - Austria 1
IQ - Iraq 1
JP - Giappone 1
KZ - Kazakistan 1
LU - Lussemburgo 1
RO - Romania 1
SI - Slovenia 1
TR - Turchia 1
Totale 4.834
Salva come PNG Salva come JPEG
Città #
Dublin 516
Jacksonville 480
Chandler 396
Nanjing 350
Nanchang 156
Boardman 149
Ashburn 126
Shenyang 120
Princeton 107
Jiaxing 103
Wilmington 103
Changsha 97
Lawrence 95
Hebei 92
Beijing 84
Medford 81
Tianjin 64
Hangzhou 51
Helsinki 36
Shanghai 23
Norwalk 22
Seattle 21
Toronto 19
Woodbridge 13
Fairfield 12
Des Moines 11
New York 11
Ann Arbor 10
Jinan 10
Kunming 8
Pune 8
Dearborn 7
Milan 7
Singapore 7
Amman 6
Eindhoven 6
Lanzhou 6
Los Angeles 6
San Francisco 6
Verona 6
Ningbo 5
Rome 5
Taizhou 5
Halifax 4
Orange 4
Tehran 4
Washington 4
Fuzhou 3
Guangzhou 3
Zhengzhou 3
Christchurch 2
Haikou 2
Molfetta 2
Salerno 2
Aberdare 1
Atella 1
Atlanta 1
Bari 1
Cavacurta 1
Clifton 1
Dallas 1
Falkenstein 1
Giugliano In Campania 1
Issy-les-moulineaux 1
Leawood 1
Ljubljana 1
London 1
Luxembourg 1
Meda 1
Misinto 1
Nelson 1
Orzivecchi 1
Osaka 1
Palermo 1
Prineville 1
Redwood City 1
Rockville 1
Santa Clara 1
Tappahannock 1
Trieste 1
Vienna 1
Wuhan 1
Totale 3.507
Salva come PNG Salva come JPEG
Nome #
Comparison between diet, orlistat and fluvastatin in obese patients with mild hypertension and hypercholesterolemia 85
Confronto tra dieta, orlistat e fluvastatina in soggetti obesi, con ipertensione arteriosa lieve e ipercolesterolemia 78
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 73
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 71
Confronto tra nateglinide più metformina rispetto a glibenclamide più metformina sul metabolismo glucidico nei pazienti diabetici di tipo 2: studio ad 1 anno 71
Confronto tra pioglitazone e rosiglitazone sul metabolismo glucidico e lipidico nei soggetti diabetici di tipo 2 in terapia con metformina 70
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 66
Actions of glimepiride plus metformin compared to rosiglitazone plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients. 66
Comparison between orlistat and sibutramine in obese patients with mild hypertension 64
Changes during glimepiride plus rosiglitazone vs glibenclamide plus rosiglitazone treatment on glucose metabolism and lipoprotein (a) in Type 2 diabetic patients. 64
Effects of rosiglitazone alone and in association with simvastatin on lipid and lipoprotein parameters in patients with metabolic syndrome 64
Comparison between fosinopril and eprosartan on lipid profile and Lp(a) in normotensive, type 2 diabetic subjects, with microalbuminuria 63
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 62
Comparison between glimepiride plus pioglitazone vs. glimepiride plus rosiglitazone on glucose metabolism and on lipid, lipoprotein and apolipoprotein fractions in type 2 diabetic patients 61
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 61
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 61
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 61
Efficacy of fluvastatin together with fenofibrate in hypercholesterolemic type 2 diabetic subjects compared to monotherapy. 61
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 60
Fosinopril vs eprosartan in normotensive, Type 2 diabetic patients, with microalbuminuria 60
Metalloproteasi-2, metalloproteasi-9 ed inibitore tissutale delle metalloproteasi-1 in pazienti ipertesi 60
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolismo glucidico e lipidico nei soggetti obesi diabetici di tipo 2 59
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 59
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 58
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients 58
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 58
Effetti di pioglitazone e rosiglitazone nei pazienti con diabete di tipo 2 e sindrome metabolica trattati con metformina 57
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 56
Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1, -2 in healthy and type 2 diabetic subjects 56
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic insulin-resistant patients 56
MMP-2, -9 and TIMP-1 in patients with hypertension before and after doxazosin therapy 56
La terapia con rosiglitazone migliora i parametri di insulino-resisitenza nei pazienti diabetici in sovrappeso ed obesi intolleranti alla metformina 55
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 55
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 55
Glycemic and extraglycemic effects of glimepiride plus pioglitazone vs glimepiride plus rosiglitazone therapy in Type 2 diabetic patients 54
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy 54
Efficacia di fluvastatina e fenofibrato in prevenzione secondaria rispetto alla monoterapia: studio ad 1 anno in pazienti diabetici di tipo 2, ipercolesterolemici 54
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 54
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects 54
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 53
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 53
Le metalloproteasi-2, -9 in differenti gruppi con e senza diabete 53
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 52
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 52
Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes 52
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 52
Effects of exenatide compared to glibenclamide on glycemic control and on insulin resistance in type 2 diabetic patients with metformin therapy 51
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients: a 1 year 51
Atorvastatin-amlodipine combination and fibrinolytic balance in hypertensive hypercholesterolemic insulin-resistent patients 51
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 50
Effetti metabolici di telmisartan e irbesartan nei apzienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 50
Pioglitazone and sitagliptin compared to pioglitazone and metfomin therapy on glycaemic control and on insulin resistance in type 2 diabetic patients 49
Efficacy of fluvastatin together with fenofibrate in secondary prevention compared to monotherapy in hypercholesterolemic, type 2 diabetic subjects: A 1-year study 49
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 49
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 49
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 49
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism and lipoprotein (a) in type 2 diabetic patients: A 1-year study 49
Le metalloprotesi -2 e -9 e i loro inibitori tissutali -1 e -2 nei soggetti sani e nei soggetti con diabete di tipo 2 49
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 49
Comparison between glimepiride plus metformin vs rosiglitazone plus metformin on glucose metabolism and on blood pressure in Type 2 diabetic patients 49
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 48
Matrix metalloproteinase 2 and 9 levels in diabetic and nondiabetic patients during and after acute coronary syndrome 47
Effects of telmisartan compared to nifedipine in hypertensive, type 2 diabetic patients on glucose metabolism and lipid profile: a 1-year study 47
Matrix metalloproteinase-2, -9 and tissue inhibitor Metalloproteinase-1 in patients with hypertension 47
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 47
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 47
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 46
Il sistema di monitoraggio continuo della glicemia nei soggetti sani: risultato di uno studio pilota 46
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 46
Terapia con telmisartan e irbesartan nei pazienti con diabete di tipo 2 trattati con rosiglitazone: effetti sull'insulino-resistenza, leptina e TNF-alfa 46
La sibutramina non modifica i parametri emodinamici bnegli obesi, diabetici di tipo 2 46
Comparison between Glimepiride Plus Rosiglitazone on Glucose Metabolism and on Lipid, Lipoprotein and Apolipoprotein Parameters in Type 2 Diabetic Patients 46
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 45
Le metalloproteasi-2, -9 nei pazienti diabetici con sindrome coronarica prima e dopo l'evento acuto 44
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 44
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 44
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in patients with acute coronary syndrome with or without diabetes during and after acute event 44
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 43
Metabolic and insulin resistance-related indices during pioglitazone and vildagliptin association versus glimepiride and vildagliptin association in type 2 diabetic patients 43
Glycemic control and cardiovascular risk profile in patients with type 2 diabetes treated with repaglinide or metformin 42
Stress ossidativo e rischio vascolare. Quale ruolo per gli antiossidanti? 42
Lipid and lipoprotein effects of rosiglitazone alone and in association with simvastatin in patients with metabolic syndrome 40
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolsimo glucidico e lipidico nei soggettiobesi diabetici di tipo 2 40
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 37
Valutazione delle metalloproteasi 2 e 9 in differenti gruppi di pazienti con o senza diabete 35
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 35
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 35
The improvement of Insulin-Resistance with Rosiglitazone Plus Metformin Compared to Glimepiride Plus Metformin Lowers Blood Pressure Values in Type 2 Diabetic Patients 35
Effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin 31
Fenofibrate and fluvastatin compared to monotherapy in hypercholesterolemic diabetic patients with coronary heart disease: a 1 year study 30
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on markers of cardiovascular disease 28
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 28
Effects of Telmisartan Compared to Nifedipine in Hypertensive, Type 2 Diabetic Patients on Glucose Metabolism and Lipid Profile: A 1-Year Study 28
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 27
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 24
Totale 4.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.853
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.853
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.061 0 639 0 71 1 82 19 82 3 108 56 0
2020/2021650 81 64 15 67 0 87 0 111 15 98 95 17
2021/2022350 0 0 18 1 1 0 4 23 12 2 69 220
2022/20231.329 121 105 2 67 129 139 0 86 602 7 47 24
2023/2024410 30 103 19 32 32 103 5 43 3 12 12 16
2024/2025109 8 101 0 0 0 0 0 0 0 0 0 0
Totale 4.854